183 related articles for article (PubMed ID: 35422397)
1. Medullary thyroid cancer - An update.
Fugazzola L
Best Pract Res Clin Endocrinol Metab; 2023 Jan; 37(1):101655. PubMed ID: 35422397
[TBL] [Abstract][Full Text] [Related]
2. Other markers of medullary thyroid cancer, not only calcitonin.
Censi S; Manso J; Mian C
Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36651167
[TBL] [Abstract][Full Text] [Related]
3. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D
Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114
[TBL] [Abstract][Full Text] [Related]
4. Medullary Thyroid Carcinoma: Prognostic Variables And Tumour Markers Affecting Survival.
Hassan A; Siddique M; Riaz S; Khan AI; Nawaz MK; Bashir H
J Ayub Med Coll Abbottabad; 2018; 30(Suppl 1)(4):S627-S632. PubMed ID: 30838820
[TBL] [Abstract][Full Text] [Related]
5. Sporadic medullary thyroid carcinoma associated with toxic multinodular goitre.
Small PK; Smith D
J R Coll Surg Edinb; 1997 Jun; 42(3):199-200. PubMed ID: 9195818
[TBL] [Abstract][Full Text] [Related]
6. Current Guidelines for Management of Medullary Thyroid Carcinoma.
Kim M; Kim BH
Endocrinol Metab (Seoul); 2021 Jun; 36(3):514-524. PubMed ID: 34154310
[TBL] [Abstract][Full Text] [Related]
7. Use of fine-needle aspirate calcitonin to detect medullary thyroid carcinoma: A systematic review.
Trimboli P; Guidobaldi L; Bongiovanni M; Crescenzi A; Alevizaki M; Giovanella L
Diagn Cytopathol; 2016 Jan; 44(1):45-51. PubMed ID: 26481456
[TBL] [Abstract][Full Text] [Related]
8. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
9. [PREOPERATIVE DIAGNOSTICS OF THYROID MEDULLARY CARCINOMA WITH EMPHASIS ON CYTOMORPHOLOGICAL FEATURES AND DIFFERENTIAL DIAGNOSIS OF PRIMARY AND SECONDARY THYROID TUMORS].
Katović SK; Vasilj A
Acta Med Croatica; 2014 Dec; 68(4-5):383-8. PubMed ID: 26285471
[TBL] [Abstract][Full Text] [Related]
10. Medullary thyroid carcinoma: a narrative historical review.
Wong A; Nabata K; Wiseman SM
Expert Rev Anticancer Ther; 2022 Aug; 22(8):823-834. PubMed ID: 35694971
[TBL] [Abstract][Full Text] [Related]
11. Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review.
Gambardella C; Offi C; Clarizia G; Romano RM; Cozzolino I; Montella M; Di Crescenzo RM; Mascolo M; Cangiano A; Di Martino S; Candela G; Docimo G
BMC Endocr Disord; 2019 Oct; 19(1):103. PubMed ID: 31619220
[TBL] [Abstract][Full Text] [Related]
12. Appropriate and mindful measurement of serum calcitonin in patients with thyroid nodules. A white paper.
Trimboli P; Valderrabano P; Pitoia F; Piccardo A; Bojunga J
Endocrine; 2024 Jan; 83(1):60-64. PubMed ID: 37589814
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.
Maia AL; Siqueira DR; Kulcsar MA; Tincani AJ; Mazeto GM; Maciel LM
Arq Bras Endocrinol Metabol; 2014 Oct; 58(7):667-700. PubMed ID: 25372577
[TBL] [Abstract][Full Text] [Related]
14. Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules.
Verbeek HH; de Groot JWB; Sluiter WJ; Muller Kobold AC; van den Heuvel ER; Plukker JT; Links TP
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD010159. PubMed ID: 32176812
[TBL] [Abstract][Full Text] [Related]
15. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
Dabelić N; Jukić T; Fröbe A
Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
[TBL] [Abstract][Full Text] [Related]
16. Ultrasonographic Features of Medullary Thyroid Carcinoma: Do they Correlate with Pre and PostOperative Calcitonin Levels?
Cho KE; Gweon HM; Park AY; Yoo MR; Kim J; Youk JH; Park YM; Son EJ
Asian Pac J Cancer Prev; 2016; 17(7):3357-62. PubMed ID: 27509975
[TBL] [Abstract][Full Text] [Related]
17. Molecular signatures of medullary thyroid carcinoma by matrix-assisted laser desorption/ionisation mass spectrometry imaging.
Smith A; Galli M; Piga I; Denti V; Stella M; Chinello C; Fusco N; Leni D; Manzoni M; Roversi G; Garancini M; Pincelli AI; Cimino V; Capitoli G; Magni F; Pagni F
J Proteomics; 2019 Jan; 191():114-123. PubMed ID: 29581064
[TBL] [Abstract][Full Text] [Related]
18. Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
Raue F; Frank-Raue K
Clin Cancer Res; 2016 Oct; 22(20):5012-5021. PubMed ID: 27742787
[TBL] [Abstract][Full Text] [Related]
19. Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.
Matrone A; Gambale C; Prete A; Elisei R
Front Endocrinol (Lausanne); 2022; 13():864253. PubMed ID: 35422765
[TBL] [Abstract][Full Text] [Related]
20. Calcitonin negative Medullary Thyroid Carcinoma: a challenging diagnosis or a medical dilemma?
Gambardella C; Offi C; Patrone R; Clarizia G; Mauriello C; Tartaglia E; Di Capua F; Di Martino S; Romano RM; Fiore L; Conzo A; Conzo G; Docimo G
BMC Endocr Disord; 2019 May; 19(Suppl 1):45. PubMed ID: 31142313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
